Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Anthony, Schwarer"'
Autor:
Ing Soo Tiong, Meaghan Wall, Ashish Bajel, Akash Kalro, Shaun Fleming, Andrew W. Roberts, Nisha Thiagarajah, Chong Chyn Chua, Maya Latimer, David Yeung, Paula Marlton, Amanda Johnston, Anoop Enjeti, Chun Yew Fong, Gavin Cull, Stephen Larsen, Glen Kennedy, Anthony Schwarer, David Kipp, Sundra Ramanathan, Emma Verner, Campbell Tiley, Edward Morris, Uwe Hahn, John Moore, John Taper, Duncan Purtill, Pauline Warburton, William Stevenson, Nicholas Murphy, Peter Tan, Ashanka Beligaswatte, Howard Mutsando, Mark Hertzberg, Jake Shortt, Ferenc Szabo, Karin Dunne, Andrew H. Wei, Australasian Leukaemia and Lymphoma Group (ALLG)
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract Despite an increasing desire to use historical cohorts as “synthetic” controls for new drug evaluation, limited data exist regarding the comparability of real-world outcomes to those in clinical trials. Governmental cancer data often lac
Externí odkaz:
https://doaj.org/article/8934e2c0d348469ca8fbc945fd4e9089
Autor:
Othman Al-Sawaf, Sandra Robrecht, Can Zhang, Stefano Olivieri, Yi Meng Chang, Anna-Maria Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Karl-Anton Kreuzer, Liliya Sivcheva, Carsten Niemann, Anthony Schwarer, Javier Loscertales Pueyo, Robert Weinkove, Dirk Strumberg, Allanah Kilfoyle, Eva Runkel, Barbara Eichhorst, Stephan Stilgenbauer, Yanwen Jiang, Michael Hallek, Kirsten Fischer
Publikováno v:
HemaSphere, Vol 7, p e064430a (2023)
Externí odkaz:
https://doaj.org/article/69b7c9662b2f4c66bf1d9a50ff0a94d2
Autor:
Laura Cicconi, Anna Maria Testi, Pau Montesinos, Eduardo Rego, Hong Hu Zhu, Hiroyuki Takahashi, Michael Dworzak, Elihu Estey, Anthony Schwarer, Jordi Esteve, Ombretta Annibali, Roberto Castelli, Milena Mirabile, Mario Angelini, Vladimir Lazarevic, Jeevan Kumar, Giuseppe Avvisati, Carmelo Gurnari, Franco Locatelli, Maria Teresa Voso, Miguel Angel Sanz, Francesco Lo-Coco, Oussama Abla
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 10, Pp 1-4 (2021)
Externí odkaz:
https://doaj.org/article/952825a19cbd4a4cadc9a98a15926e56
Autor:
Lucy C. Fox, Katherine D. Cummins, Ben Costello, David Yeung, Rebecca Cleary, Cecily Forsyth, Maciek Tatarczuch, Kate Burbury, Olga Motorna, Jake Shortt, Shaun Fleming, Andrew McQuillan, Anthony Schwarer, Rosemary Harrup, Amy Holmes, Sumita Ratnasingam, Kah-Lok Chan, Wei-Hsun Hsu, Asma Ashraf, Faye Putt, Andrew Grigg
Publikováno v:
Blood Advances, Vol 1, Iss 13, Pp 802-811 (2017)
Abstract: Dasatinib has shown superiority over imatinib in achieving molecular responses (MRs) in chronic phase chronic myeloid leukemia but with a different toxicity profile, which may impact its overall benefit. Reported toxicities include pleural
Externí odkaz:
https://doaj.org/article/80ddfac2f5cf487793c7b79283709231
Publikováno v:
Blood. 140:3900-3901
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cf53e5ec1f2daa5a01bd572cb00236a4
https://doi.org/10.1182/blood-2022-168855
https://doi.org/10.1182/blood-2022-168855
Autor:
Lynette C.Y. Chee, Nora Lee, Andrew Grigg, Melissa Chen, Anthony Schwarer, Jeff Szer, David T Yeung, Timothy Hughes, Naranie Shanmuganathan
Asciminib is the first tyrosine kinase inhibitor (TKI) to Specifically Target the ABL Myristoyl Pocket (STAMP). In the ASCEMBL Phase 3 randomised study comparing asciminib to bosutinib in patients with CML in chronic phase (CP) after ³2 prior TKIs,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fbeb9274c847e80c9e4b44851795fd5
https://hdl.handle.net/11541.2/33196
https://hdl.handle.net/11541.2/33196
Autor:
Chong C, Chua, Andrew, Grigg, Jasmine, Singh, Mark P, Droogleever, Lan, Zhang, Andrew, Lim, Chun Y, Fong, Stephen B, Ting, Anthony, Schwarer, Ing S, Tiong, Andrew H, Wei
Publikováno v:
Leukemialymphoma. 61(4)
Recent regulatory approval of midostaurin, a FLT3 targeting small molecular inhibitor, will likely lead to increased use of midostaurin in combination with intensive chemotherapy for patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d4614a7a87bd8f960bb7c07527ca1f9b
https://pubmed.ncbi.nlm.nih.gov/31752581
https://pubmed.ncbi.nlm.nih.gov/31752581
Autor:
Babak, Tamjid, Joseph, Mckendrick, Anthony, Schwarer, Rowan, Doig, Philip, James, Patrick, Hosking, Eliza A, Hawkes
Publikováno v:
Asia-Pacific journal of clinical oncology. 13(3)
Relapsed/refractory (R/R) aggressive lymphoma outcomes are poor. There is no standard treatment. PACEBOM (prednisolone, doxorubicin, cyclophosphamide, etoposide, bleomycin, vincristine and methotrexate) has shown efficacy for several lymphoma subtype
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4a669d887d8879cd10d16492cb97a762
https://pubmed.ncbi.nlm.nih.gov/28004881
https://pubmed.ncbi.nlm.nih.gov/28004881
Autor:
Simon J, Harrison, Hang, Quach, Emma, Link, Huaibao, Feng, Joanne, Dean, Michael, Copeman, Helgi, Van De Velde, Anthony, Schwarer, Bartrum, Baker, Andrew, Spencer, John, Catalano, Philip, Campbell, Bradley, Augustson, Ken, Romeril, Henry Miles, Prince
Publikováno v:
American journal of hematology. 90(5)
Despite the common practice of combining dexamethasone (Dex) with bortezomib (Bz) in patients with multiple myeloma (MM), until now there has been few prospective trials undertaken. We undertook a trial that recapitulated the original APEX study exce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f09a3ac9321c178396ace5b2879d0aca
https://pubmed.ncbi.nlm.nih.gov/25651830
https://pubmed.ncbi.nlm.nih.gov/25651830
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.